AbbVie Gets Humira Erosion Right, But Skyrizi/Rinvoq Disappoint Investors

 
• By Joseph Haas
Sales decline
Humira suffered significant biosimilar erosion during Q1, but it was in line with projections • Source: Shutterstock

More from Earnings

More from Business